Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84.
Article PubMed CAS Google Scholar
Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94.
Article PubMed CAS Google Scholar
McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):1242–8.
McGonagle D. Enthesitis: An autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatology Venereol. 2009;23(SUPPL. 1):9–13.
Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science (80- ). 2010;327(5966):656–61.
Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clin Dev Immunol. 2013;2013(968549):1–13.
Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(SUPPL. 2):26–9.
Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14(4):286–92.
Article PubMed CAS Google Scholar
Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: A unique pathway in immune-mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133–42.
Article PubMed PubMed Central CAS Google Scholar
Rosine N, Miceli-Richard C. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis? Front Immunol. 2021;11(January):1–12.
Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheum. 2014;66(5):1272–81.
Jadon DR, Stober C, Pennington SR, FitzGerald O. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat Rev Rheumatol. 2020;16(11):609–27.
Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatol (United Kingdom). 2019;58(2):336–44.
Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol. 2015;181(3):401–6.
Article PubMed PubMed Central CAS Google Scholar
Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YCM, Maari C, et al. Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. J Invest Dermatol. 2021;141(7):1707–18.
Liu Y, Jarjour W, Olsen N, Zheng SG. Traitor or warrior–Treg cells sneaking into the lesions of psoriatic arthritis. Clin Immunol. 2020;215(March):108425.
Article PubMed CAS Google Scholar
Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, et al. CD4+CD25 highCD127 low/- Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2517–21.
Article PubMed CAS Google Scholar
Yun WJ, Lee DW, Chang SE, Yoon GS, Huh JR, Won CH, et al. Role of CD4+CD25high+FOXP3+ regulatory T cells in psoriasis. Ann Dermatol. 2010;22(4):397–403.
Article PubMed PubMed Central Google Scholar
Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, et al. Dysfunctional Blood and Target Tissue CD4 + CD25 high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation. J Immunol. 2005;174(1):164–73.
Article PubMed CAS Google Scholar
Højgaard P, Ellegaard K, Nielsen SM, Christensen R, Guldberg-Møller J, Ballegaard C, et al. Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care Res. 2019;71(6):798–810.
Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12(3):191–200.
Article PubMed PubMed Central CAS Google Scholar
Ye W, Lu W, Tang Y, Chen G, Li X, Ji C, et al. Identification of COVID-19 Clinical Phenotypes by Principal Component Analysis-Based Cluster Analysis. Front Med. 2020;7(November):1–7.
Yoon HJ, Kang J, Park H, Sohn I, Lee SH, Lee HY. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. PLoS One. 2020;15(4):1–13.
Peres-Neto PR, Jackson DA, Somers KM. How many principal components? stopping rules for determining the number of non-trivial axes revisited. Comput Stat Data Anal. 2005;49(4):974–97.
Lee JH, Kim B, Jin WJ, Kim HH, Ha H, Lee ZH. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: Relevance for arthritis. Arthritis Res Ther. 2017;19(1):1–14.
Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol. 2009;27(1):22–7.
Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876–85.
Article PubMed CAS Google Scholar
Colombo E, Galleri G, Erre GL, Piras C, Biondi G, Taras L, et al. Peripheral blood CD8+ T-cell profiles in patients with psoriatic arthritis: A cross-sectional case-control study. Eur Rev Med Pharmacol Sci. 2017;21(22):5166–71.
Diani M, Casciano F, Marongiu L, Longhi M, Altomare A, Pigatto PD, et al. Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. Sci Rep. 2019;9(1):1–10.
FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: Genotype determines clinical phenotype. Arthritis Res Ther. 2015;17(1):1–11.
Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, et al. Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem. 2013;288(38):27059–67.
Article PubMed PubMed Central CAS Google Scholar
Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178(5):1003–5.
Article PubMed CAS Google Scholar
Dolcino M, Ottria A, Barbieri A, Patuzzo G, Tinazzi E, Argentino G, et al. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):1–33.
Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheum. 2015;67(4):934–44.
O’Brien-Gore C, Gray EH, Durham LE, Taams LS, Kirkham BW. Drivers of Inflammation in Psoriatic Arthritis: the Old and the New. Curr Rheumatol Rep. 2021;23(6):1–11.
留言 (0)